The relationship between body mass index and mental disorders in the adult population

The purpose of the work is to study the features of the body mass index (BMI) in schizophrenia patients (SP) who live in Chuvashia.

Material and methods. 607 SP were examined (307 men and 300 women) aged 18 to 82 (average - 44.51 ± 12.3 years). The diagnosis of schizophrenia met the criteria for ICD-10 (F20-29); disease duration ranged from 0 to 52 years (mean - 18.9 ± 10.7 years). BMI was taken into account according to the Ketle index. For each SP, a survey card with clinical, therapeutic, and socio-demographic indices was filled out. The comparison group included a sample of 3417 residents of Chuvashia. Mathematical and statistical processing was carried out using descriptive statistics and χ² distribution.

Results. 9.2% of SP had underweight, 54.2% - normal body weight, 36.6% - excess body weight and obesity. Among women there were significantly more persons with increased BMI and obesity, among men - with normal BMI. In SP, BMI did not depend on the group of taken antipsychotics (typical, atypical, mixed-use) and the disease’s duration. With patients’ age, BMI increased to excess BMI (25-29.9 kg/m2). Among SP, persons with underweight were much more common (among healthy people, 2% vs 9.2% in SP). From 40 years of age and older, among the healthy population, persons with an increased BMI and obesity begin to predominate significantly compared with the SP group. Observations of BMI during inpatient treatment from 1.5 to 22 months showed multidirectional dynamics, including increased body weight in 42.2% of SP, a decrease in 30.1%, without changes in BMI in 27.7%; it was not possible to retrospectively identify any patterns of BMI fluctuations.

Conclusion. The revealed paradoxes of BMI for SP in Chuvashia, especially a high proportion of SP with underweight, require refinement considering ethnic, genetic, sex and age, hormon and metabolic factors.

1. NCD Risk Factor Collaboration (NCD-RisC) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016; 387(10026): 1377–96. https://doi.org/10.1016/S0140-6736(16)30054-X

2. Tek Ts., Kutsukgontsu S., Guloksuz S., Vuds S.V., Srikhari V.Kh., Annamalay A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Sotsial’naya i klinicheskaya psikhiatriya, 2016; 26(1): 45–9. (in Russian)

3. Chiliza B., Asmal L., Oosthuizen P., van Niekerk E., Erasmus R., Kidd M., et al. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic. Eur. Psychiatry. 2015; 30(2): 277–83. https://doi.org/10.1016/j.eurpsy.2014.11.013

4. Gu X.J., Chen R., Sun C.H., Zheng W., Yang X.H., Wang S.B., et al. Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials. J. Int. Med. Res. 2017; 46(1): 22–32. https://doi.org/10.1177/0300060517716783

5. Sugai T., Suzuki Y., Yamazaki M., Shimoda K., Mori T., Ozeki Y., et al. High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia: a nationwide survey. BMJ Open. 2015; 5(12): e008720. https://doi.org/10.1136/bmjopen-2015-008720

6. Manu P., Dima L., Shulman M., Vancampfort D., De Hert M., Correll C.U. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr. Scand. 2015; 132(2): 97–108. https://doi.org/10.1111/acps.12445

7. Pillinger T., McCutcheon R.A., Vano L., Mizuno Y., Arumuham A.,Hindley G., et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020; 7(1): 64–77. https://doi.org/10.1016/S2215-0366(19)30416-X

8. Al Kibria G.M. Prevalence and factors affecting underweight, overweight and obesity using asian and world health organization cutoffs among adults in Nepal: analysis of the Demographic and Health Survey 2016. Obes Res. Clin. Pract. 2019; 13(2): 129–36. https://doi.org/10.1016/j.orcp.2019.01.006

9. Eskelinen S., Sailas E., Joutsenniemi K., Holi M., Suvisaari J. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia. Nord. J. Psychiatry. 2015; 69(5): 339–45. https://doi.org/10.3109/08039488.2014.983544

10. Bora E., Akdede B.B., Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol. Med. 2017; 47(6): 1030–40. https://doi.org/10.1017/S0033291716003366

11. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr. Bull. 2013; 39(2): 306–18. https://doi.org/10.1093/schbul/sbr148

12. Inamura Y., Sagae T., Nakamachi K., Murayama N. Body mass index of inpatients with schizophrenia in Japan. Int. J. Psychiatry Med. 2012; 44(2): 171–81. https://doi.org/10.2190/PM.44.2.h

13. Inamura Y., Sagae T., Kushida O., Nakamachi K., Murayama N. Survey of obesity and underweight among inpatients with schizophrenia in psychiatric hospitals throughout Japan. Seishin Shinkeigaku Zasshi. 2013; 115(1): 10–21. (in Japanese)

14. Sugai T., Suzuki Y., Yamazaki M., Shimoda K., Mori T., Ozeki Y., et al. High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients With Schizophrenia: A Nationwide Survey. PLoS One. 2016; 11(11): e0166429. https://doi.org/10.1371/journal.pone.0166429

15. Xiu M.H., Li H., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009; 33(8): 1508–12. https://doi.org/10.1016/j.pnpbp.2009.08.011

16. Wang J., Zhang Y, Yang Y., Liu Z., Xia L., Li W., et al. The prevalence and independent influencing factors of obesity and underweight in patients with schizophrenia: a multicentre cross-sectional study. Eat. Weight Disord. 2020. https://doi.org/10.1007/s40519-020-00920-9

17. Padmavati R., McCreadie R.G., Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr. Res. 2010; 121(1-3): 199–202. https://doi.org/10.1016/j.schres.2010.05.010

18. Suzuki Y., Sugai T., Fukui N., Watanabe J., Ono S., Tsuneyama N., et al. High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia psychiatry. Clin. Neurosci. 2014; 68(1): 78–82. https://doi.org/10.1111/pcn.12082

19. Sugawara N., Maruo K., Sugai T., Suzuki Y., Ozeki Y., Shimoda K., et al. Prevalence of underweight in patients with schizophrenia: a meta-analysis. Schizophr. Res. 2018; 195: 67–73. https://doi.org/10.1016/j.schres.2017.10.017

20. Kitabayashi Y., Narumoto J., Kitabayashi M., Fukui K. Body mass index among Japanese inpatients with schizophrenia. Int. J. Psychiatry Med. 2006; 36(1): 93–102. https://doi.org/10.2190/3V6L-82AU-X663-NWXN.

21. Yang F., Wang K., Du X., Deng H., Wu H.E., Yin G., et al. Sex difference in the association of body mass index and BDNF le­vels in Chinese patients with chronic schizophrenia. Psychopharmacology (Berl). 2019; 236(2): 753–62. https://doi.org/10.1007/s00213-018-5107-1

22. Mezquida G., Savulich G., Garcia-Rizo C., Garcia-Portilla M.P., Toll A., Garcia-Alvarez L., et al. Inverse association between negative symptoms and body mass index in chronic schizophrenia. Schizophr. Res. 2018; 192: 69–74. https://doi.org/10.1016/j.schres.2017.04.002

23. Park S.C., Tripathi A., Avasthi A., Grover S., Tanra A.J., Kato T.A., et al. Relationship between body mass index and extrapyramidal symptoms in asian patients with schizophrenia: The Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP). Psychiatr. Danub. Summer. 2020; 32(2): 176–86. https://doi.org/10.24869/psyd.2020.176

24. Nagamine T., Ido Y., Nakamura M., Okamura T. 4(G)-β-D-galactosylsucrose as a prebiotics may improve underweight in inpatients with schizophrenia. Biosci. Microbiota Food Health. 2018; 37(2): 45–7. https://doi.org/10.12938/bmfh.17-016

25. Haga T., Ito K., Sakashita K., Iguchi M., Ono M., Tatsumi K. Risk factors for pneumonia in patients with schizophrenia. Neuropsychopharmacol. Rep. 2018; 38(4): 204–9. https://doi.org/10.1002/npr2.12034

26. Aune D., Sen A., Norat T., Janszky I., Romundstad P., Tonstad S., et al. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation. 2016; 133(7): 639–49. https://doi.org/10.1161/CIRCULATIONAHA.115.016801

27. Siskind D.J., Leung J., Russell A.W., Wysoczanski D., Kisely S. Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLoS One. 2016; 11(6): e0156208. https://doi.org/10.1371/journal.pone.0156208

28. Pearsall R., Thyarappa Praveen K., Pelosi A., Geddes J. Dietary advice for people with schizophrenia. Cochrane Database Syst. Rev. 2016; 3(3): CD009547. https://doi.org/10.1002/14651858.CD009547

29. Gorczynski P., Faulkner G. Exercise therapy for schizophrenia. Cochrane Database Syst. Rev. 2010; 12(5): CD004412. https://doi.org/10.1002/14651858.CD004412.pub2

30. Golenkov A.V., Safronov S.A., Kuznetsov S.D. Results of one-day census of patients with mental disorders in three psychiatric hospitals of Chuvashia. Sotsial’naya i klinicheskaya psikhiatriya. 2015; 25(3): 56–60. (in Russian)